A Phase 3 interventional study of Vortioxetine (Lu AA21004) and Agomelatine in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-26.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 20th largest by enrollment, is one of 3 that started in 2012, is one of 31 in phase 3, and was the 22nd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 495 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 15th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vortioxetine (Lu AA21004)
Drug: Agomelatine
encapsulated tablets, daily, orally
Also known as: Brintellix®
encapsulated tablets, daily, orally
Also known as: Valdoxan®
Change From Baseline in MADRS Total Score at Week 8
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
Change From Baseline in MADRS Total Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in HAM-A Total Score at Week 8
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
Change From Baseline in HAM-A Total Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in CGI-S Score at Week 8
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
Change From Baseline in CGI-S Score at Week 12
Time frame: Baseline and Week 12
Change in Clinical Status Using CGI-I Score at Week 8
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.
Time frame: Week 8
Change in Clinical Status Using CGI-I Score at Week 12
Time frame: Week 12
Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame: Baseline and Week 8
Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame: Baseline and Week 12
Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)
Time frame: Week 8
Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)
Time frame: Week 12
Change From Baseline in SDS Total Score at Week 8
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
Change From Baseline in SDS Total Score at Week 12
Time frame: Baseline and Week 12
In- or outpatients who had been treated with antidepressant selective serotonin reuptake inhibitor (SSRI) or selective noradrenaline reuptake inhibitor (SNRI) monotherapy that was prescribed to treat a single episode of Major Depressive Disorder (MDD) or recurrent MDD.
| Milestone | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Started | 253 | 242 |
| Completed | 200 | 179 |
| Not completed | 53 | 63 |
| Withdrew: Adverse event | 15 | 23 |
| Withdrew: Lack of efficacy | 11 | 17 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Withdrew: Protocol violation | 5 | 7 |
| Withdrew: Withdrawal of consent | 14 | 12 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative or other reason(s) | 5 | 4 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in MADRS Total Score at Week 8 | -16.53 ± 0.48 | -14.38 ± 0.51 |
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in MADRS Total Score at Week 12 | -18.95 ± 0.50 | -16.92 ± 0.53 |
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in HAM-A Total Score at Week 8 | -11.68 ± 0.39 | -9.79 ± 0.42 |
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in HAM-A Total Score at Week 12 | -13.52 ± 0.40 | -11.59 ± 0.42 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in CGI-S Score at Week 8 | -1.84 ± 0.07 | -1.55 ± 0.07 |
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in CGI-S Score at Week 12 | -2.20 ± 0.07 | -1.93 ± 0.07 |
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change in Clinical Status Using CGI-I Score at Week 8 | 1.97 ± 0.06 | 2.22 ± 0.07 |
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change in Clinical Status Using CGI-I Score at Week 12 | 1.74 ± 0.06 | 1.99 ± 0.07 |
| percentage of participants | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline) | 61.5 | 47.3 |
| percentage of participants | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline) | 69.8 | 56.0 |
| percentage of participants | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10) | 40.5 | 29.5 |
| percentage of participants | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10) | 55.2 | 39.4 |
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in SDS Total Score at Week 8 | -9.28 ± 0.53 | -7.06 ± 0.55 |
| units on a scale | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg |
|---|---|---|
| Change From Baseline in SDS Total Score at Week 12 | -10.99 ± 0.55 | -9.24 ± 0.58 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | — | 3/253 (1.2%) | 82/253 (32.4%) |
| Agomelatine | — | 4/242 (1.7%) | 77/242 (31.8%) |
| Event | Vortioxetine | Agomelatine |
|---|---|---|
| MetrorrhagiaReproductive system and breast disorders | 0/195 | 1/175 |
| Gamma-glutamyltransferase increasedInvestigations | 0/253 | 1/242 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/253 | 1/242 |
| Social stay hospitalisationSocial circumstances | 0/253 | 1/242 |
| Peptic ulcer perforationGastrointestinal disorders | 1/253 | 0/242 |
| Oedema peripheralGeneral disorders | 1/253 | 0/242 |
| AnxietyPsychiatric disorders | 1/253 | 0/242 |
| DepressionPsychiatric disorders | 1/253 | 0/242 |
| Event | Vortioxetine | Agomelatine |
|---|---|---|
| NauseaGastrointestinal disorders | 41/253 | 22/242 |
| HeadacheNervous system disorders | 26/253 | 32/242 |
| DizzinessNervous system disorders | 18/253 | 28/242 |
| SomnolenceNervous system disorders | 10/253 | 19/242 |
Age and Gender: All-patients-treated set (APTS) - all patients in the APRS who took at least one dose of investigational medicinal product (IMP). Study Specific Characteristics: Full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the MADRS total score.
| Age, Continuous(years) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Mean | 47.0 ± 12.4 | 45.6 ± 12.4 | 46.3 ± 12.4 |
| Sex: Female, Male(Participants) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Female | 195 | 175 | 370 |
| Male | 58 | 67 | 125 |
| MADRS: Baseline Total Score(units on a scale) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Mean | 29.1 ± 4.4 | 28.7 ± 4.0 | 28.9 ± 4.2 |
| HAM-A: Baseline Total Score(units on a scale) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Mean | 21.6 ± 6.3 | 21.4 ± 6.2 | 21.5 ± 6.2 |
| CGI-S Baseline Severity Score(units on a scale) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Mean | 4.4 ± 0.6 | 4.4 ± 0.6 | 4.4 ± 0.6 |
| SDS Total Baseline Score(units on a scale) | Vortioxetine 10 mg or 20 mg | Agomelatine 25 mg or 50 mg | Total |
|---|---|---|---|
| Mean | 19.2 ± 5.3 | 19.3 ± 5.2 | 19.3 ± 5.3 |
No study locations are listed for this record.
The record gives a start of Jan 2012 and a primary completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine